for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Medtronic PLC

MDT

現在値

127.84USD

変化

-0.89(-0.69%)

出来高

2,999,281

本日のレンジ

127.76

 - 

130.05

52週レンジ

98.94

 - 

135.89

∙ 約20分前の相場を表示しています。

適時開示

U.S. FDA Says Medtronic Recalls Pipeline Flex Embolization Devices

Sept 20 (Reuters) - FDA::FDA SAYS MEDTRONIC RECALLS PIPELINE FLEX EMBOLIZATION DEVICES FOR RISK OF DELIVERY SYSTEM FRACTURES DURING PLACEMENT, RETRIEVAL, OR MOVEMENT OF DEVICE.FDA SAYS IDENTIFIED MEDTRONIC'S RECALL OF PIPELINE FLEX EMBOLIZATION DEVICES AS A CLASS I RECALL.FDA SAYS THERE HAVE BEEN 10 SERIOUS INJURIES, AND TWO DEATHS RELATED TO RECALL OF PIPELINE FLEX EMBOLIZATION DEVICES.FDA SAYS THERE HAVE BEEN 59 REPORTED DEVICE MALFUNCTIONS RELATED TO RECALL OF PIPELINE FLEX EMBOLIZATION DEVICES.Further company coverage: MDT.N. ((Reuters.Briefs@thomsonreuters.com;)).

Axonics Announces Partial Decision On Inter Partes Review Proceedings

Sept 13 (Reuters) - Axonics Inc <AXNX.O>::AXONICS® ANNOUNCES PARTIAL DECISION ON INTER PARTES REVIEW PROCEEDINGS.AXONICS - PTAB OF U.S. PATENT AND TRADEMARK OFFICE ISSUED FINAL WRITTEN DECISIONS ON THREE OF SIX MEDTRONIC PATENTS THAT CO IS CONTESTING.AXONICS INC - PTAB AGREED WITH AXONICS ON FOUR OF FIVE CLAIMS AXONICS IS CONTESTING IN '069 PATENT.AXONICS INC - PTAB UPHELD NEARLY EXPIRED CLAIMS IN '756 PATENT AND '314 PATENT.AXONICS - PLANS TO APPEAL PTAB'S DECISIONS ON CLAIMS IT DECLINED TO INVALIDATE TO DIRECTOR OF PTO, TO U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT.

Medtronic Says CEO's 2021 Alternate Total Compensation Was $15.4 Million

Aug 27 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC PLC SAYS CHAIRMAN, CEO GEOFFREY S. MARTHA'S 2021 ALTERNATE TOTAL COMPENSATION (LTPP REPORTED IN YEAR OF GRANT) WAS $15.4 MILLION - SEC FILING.MEDTRONIC PLC SAYS FOR YEAR ENDED APRIL 30, 2021 ANNUAL TOTAL COMPENSATION FOR CEO WAS 202 TIMES THAT OF MEDIAN EMPLOYEE.

Medtronic Announces FDA Approval Of Next-Gen Tavr System For Treatment Of Symptomatic Severe Aortic Stenosis

Aug 24 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC ANNOUNCES FDA APPROVAL OF NEXT-GEN TAVR SYSTEM FOR TREATMENT OF SYMPTOMATIC SEVERE AORTIC STENOSIS.MEDTRONIC PLC - LIMITED COMMERCIAL RELEASE IS PLANNED FOR FALL WITH A FULL LAUNCH ANTICIPATED IN EARLY 2022 FOR EVOLUT TAVR PLATFORM.

Medtronic Reports Q1 EPS Of $0.56

Aug 24 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.41.Q1 GAAP EARNINGS PER SHARE $0.56.Q1 EARNINGS PER SHARE ESTIMATE $1.32 -- REFINITIV IBES DATA.QTRLY REVENUE OF $8.0 BILLION INCREASED 23% REPORTED AND 19% ORGANIC.REITERATES FY22 REVENUE GUIDANCE; RAISES LOWER END OF FY22 EPS GUIDANCE BY 5 CENTS.Q1 RESULTS REFLECT A STRONG RECOVERY FROM IMPACT OF COVID-19 PANDEMIC ON ELECTIVE PROCEDURES THAT COMPANY EXPERIENCED IN 2020.Q1 U.S. REVENUE OF $4.101 BILLION REPRESENTED 51% OF COMPANY REVENUE AND INCREASED 22%.CARDIOVASCULAR Q1 REVENUE OF $2.890 BILLION INCREASED 19% AS REPORTED AND 15% ORGANIC.CARDIAC RHYTHM & HEART FAILURE Q1 REVENUE OF $1.483 BILLION INCREASED 19% AS REPORTED AND 15% ORGANIC.IF CURRENT EXCHANGE RATES HOLD, REVENUE GROWTH IN FISCAL YEAR 2022 WOULD BE POSITIVELY AFFECTED BY APPROXIMATELY $100 TO $200 MILLION.INCREASED ITS FISCAL YEAR 2022 DILUTED NON-GAAP EPS GUIDANCE FROM PRIOR RANGE OF $5.60 TO $5.75 TO NEW RANGE OF $5.65 TO $5.75.MEDICAL SURGICAL FIRST QUARTER REVENUE OF $2.322 BILLION INCREASED 29% AS REPORTED AND 25% ORGANIC.Q1 REVENUE VIEW $7.87 BILLION -- REFINITIV IBES DATA.FY2022 EARNINGS PER SHARE VIEW $5.69, REVENUE VIEW $33.22 BILLION -- REFINITIV IBES DATA.

Medtronic Vascular Recalls Angiographic Guidewire Component Due To Being Non-Sterile

July 2 (Reuters) - U.S. FDA: :MEDTRONIC VASCULAR RECALLS ANGIOGRAPHIC GUIDEWIRE COMPONENT DUE TO BEING NON-STERILE.FDA SAYS MEDTRONIC VASCULAR RECALLING ANGIOGRAPHIC GUIDEWIRE COMPONENT BECAUSE DEVICES WERE NOT STERILIZED BEFORE BEING SHIPPED DIRECTLY TO HOSPITALS.Further company coverage: MDT.N. ((Reuters.Briefs@thomsonreuters.com;)).

United Therapeutics Says On June 22, Co, Medtronic Agreed To Discontinue Further Efforts To Develop & Commercialize Implantable System For Remodulin

June 23 (Reuters) - Medtronic PLC <MDT.N>::UNITED THERAPEUTICS - ON JUNE 22, CO, MEDTRONIC AGREED TO DISCONTINUE FURTHER EFFORTS TO DEVELOP & COMMERCIALIZE IMPLANTABLE SYSTEM FOR REMODULIN.UNITED THERAPEUTICS - DISCONTINUING FURTHER EFFORTS BASED ON EVOLUTION OF TREATMENT OPTIONS, PARADIGMS IN PULMONARY ARTERIAL HYPERTENSION OVER PAST FEW YEARS, AMONG OTHERS.UNITED THERAPEUTICS - DISCONTINUING FURTHER EFFORTS BASED ON ANTICIPATED EFFORTS REQUIRED TO SATISFY FDA’S CONDITIONS OF APPROVAL.UNITED THERAPEUTICS - CO, MEDTRONIC PLAN TO WORK TOGETHER ON A MUTUALLY-AGREED APPROACH TO WIND-DOWN THE DEVELOPMENT PROGRAM.UNITED THERAPEUTICS - THERE WERE NO PENALTIES ASSOCIATED WITH THE TERMINATION OF THE COMMERCIALIZATION AGREEMENT.Further company coverage: MDT.N. ((reuters.briefs@thomsonreuters.com;)).

Medtronic Announces FDA Approval Of Its Next Generation Recharge-Free Spinal Cord Stimulation Platform

June 10 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC ANNOUNCES FDA APPROVAL OF ITS NEXT GENERATION RECHARGE-FREE SPINAL CORD STIMULATION PLATFORM.

FDA Approves First-Of-Its-Kind Sensight™ Directional Lead System For Dbs Therapy

June 7 (Reuters) - Medtronic PLC <MDT.N>::FDA APPROVES FIRST-OF-ITS-KIND SENSIGHT™ DIRECTIONAL LEAD SYSTEM FOR DBS THERAPY.

Medtronic To Stop Distribution And Sale Of Hvad™ System

June 3 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC TO STOP DISTRIBUTION AND SALE OF HVAD™ SYSTEM.MEDTRONIC PLC - STOPPING DISTRIBUTION AND SALE OF HVAD SYSTEM EXPECTED TO BE NEUTRAL TO SLIGHTLY ACCRETIVE TO FY 2022 NON-GAAP DILUTED EPS.MEDTRONIC - PREVIOUSLY ISSUED URGENT MEDICAL DEVICE COMMUNICATION TO PHYSICIANS THAT HVAD PUMP MAY EXPERIENCE DELAY TO RESTART/FAILURE TO RESTART AFTER IT IS STOPPED.MEDTRONIC - TO STOP DISTRIBUTION IN LIGHT OF GROWING BODY OF OBSERVATIONAL CLINICAL COMPARISONS INDICATING HIGHER FREQUENCY OF NEUROLOGICAL ADVERSE EVENTS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up